General Information of Drug (ID: DMWBQKU)

Drug Name
Olprinone Drug Info
Synonyms
Olprinone; 106730-54-5; loprinone; Coretec; Olprinone [INN]; UNII-4Y8BMI9YGC; 4Y8BMI9YGC; C14H10N4O; Olprinone (INN); 5-imidazo[1,2-a]pyridin-6-yl-6-methyl-2-oxo-1H-pyridine-3-carbonitrile; 1,2-Dihydro-5-imidazo(1,2-alpha)pyridin-6-yl-6-methyl-2-oxonicotinonitrile; 1,2-dihydro-6-methyl-2-oxo-5-(imidazo[1,2-a]pyridin-6-yl)-3-pyridinecarbonitrile; AC1L1IIG; AC1Q4Q1U; SCHEMBL27661; DTXSID1048461; CHEMBL1474900; KS-00000EYK; MolPort-006-394-808; JPAWFIIYTJQOKW-UHFFFAOYSA-N; CHEBI:135019; BCP09781; ZINC38192538; HY-14254A; 3950AH
Indication
Disease Entry ICD 11 Status REF
Heart failure BD10-BD13 Approved [1]
Cross-matching ID
PubChem CID
4593
ChEBI ID
CHEBI:135019
CAS Number
CAS 106730-54-5
TTD Drug ID
DMWBQKU

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug(s) Targeting Phosphodiesterase 3 (PDE3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cilostazol DMZMSCT Intermittent claudication BD40.00 Approved [3]
Oxtriphylline DMLHSE3 Cough MD12 Approved [3]
Ibudilast DM4LSPN Castleman's disease 4B2Y Approved [4]
Enoximone DMQVZJD Congestive heart failure BD10 Approved [5]
Inamrinone Lactate DMRMFP4 Cardiac disease BA00-BE2Z Approved [6]
Milrinone DM8TUPF Congestive heart failure BD10 Approved [3]
Tofisopam DMTGNWU Hyperuricaemia 5C55.Y Phase 2 [7]
Tipelukast DMS9BDQ Asthma CA23 Phase 2 [8]
RPL-554 DMLD4VQ Allergic rhinitis CA08.0 Phase 2 [9]
Org-30029 DMDZ4R2 Heart failure BD10-BD13 Phase 2 [10]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Phosphodiesterase 3 (PDE3) TTZCG4L NOUNIPROTAC Inhibitor [2]

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2 Olprinone: a phosphodiesterase III inhibitor with positive inotropic and vasodilator effects. Cardiovasc Drug Rev. 2002 Fall;20(3):163-74.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
4 Therapeutic targeting of 3',5'-cyclic nucleotide phosphodiesterases: inhibition and beyond. Nat Rev Drug Discov. 2019 Oct;18(10):770-796.
5 In vitro and in vivo effects of the phosphodiesterase-III inhibitor enoximone on malignant hyperthermia-susceptible swine. Anesthesiology. 2003 Apr;98(4):944-9.
6 Effects of amrinone on hepatic ischemia-reperfusion injury in rats. J Hepatol. 2002 Jul;37(1):31-8.
7 The atypical anxiolytic drug, tofisopam, selectively blocks phosphodiesterase isoenzymes and is active in the mouse model of negative symptoms of psychosis. J Neural Transm (Vienna). 2010 Nov;117(11):1319-25.
8 Company report (MediciNova)
9 Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials.Lancet Respir Med.2013 Nov;1(9):714-27.
10 Effects of the positive inotropic agent Org 30029 on developed force and aequorin light transients in intact canine ventricular myocardium. Circ Res. 1993 Mar;72(3):597-606.